RxDoctor Payments Data

Matthew Reetz, DO

Family Medicine · Dover, DENPI 1306028048

Payments from drug & device makers

$548in general payments, 2019–2025

Across 22 payments — averaging $24.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Genentech USA, Inc.$159
  • Amgen$152
  • Pfizer$35
  • Novo Nordisk$35
  • Merck$34
  • Lilly USA, LLC$28
  • plus $106 from 5 others

What the payments were for

  • Food & beverage$548100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$548 in reported general payments places this provider in the 60th percentile of 352 family medicine providers in Delaware.

See all family medicine providers in Delaware

Medicare billing

Part B allowed, 2024
$209,667
Medicare patients
527
Services billed
2,736

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin99$101,110
OzempicSemaglutide66$100,932
EliquisApixaban55$56,817
FarxigaDapagliflozin Propanediol50$53,169
TrulicityDulaglutide34$51,818
JanuviaSitagliptin Phosphate36$41,311
Tresiba Flextouch U-200Insulin Degludec24$32,770
Tresiba Flextouch U-100Insulin Degludec45$28,077
Xigduo XrDapaglifloz Propaned/Metformin22$28,076
XareltoRivaroxaban18$25,981
MounjaroTirzepatide14$22,936
Synjardy XrEmpagliflozin/Metformin Hcl27$20,208
Emtricitabine-Tenofovir DisopEmtricitabine/Tenofovir (Tdf)13$19,844
Trelegy ElliptaFluticasone/Umeclidin/Vilanter18$19,604
V-Go 40Sub-Q Insulin Device, 40 Unit26$16,058

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Synjardy Xr$20$121,318126 claims
Novo NordiskOzempic$35$100,93266 claims
Lilly USA, LLCTrulicity, Mounjaro$28$74,75448 claims
PfizerEliquis, Premarin$35$62,46766 claims
AstraZenecaFarxiga$16$53,16950 claims
MerckJanuvia$34$41,31136 claims
Johnson & JohnsonXarelto$26$25,98118 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 352 family medicine providers in Delaware.

Other family medicine in Dover

See the full list for Delaware

Where these figures come from

Is this you, or does something look wrong? →